246 related articles for article (PubMed ID: 33208916)
1. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis.
Vaxman I; Sidiqi MH; Al Saleh AS; Kumar S; Muchtar E; Dispenzieri A; Buadi F; Dingli D; Lacy M; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Hogan W; Gertz M
Bone Marrow Transplant; 2021 Apr; 56(4):928-935. PubMed ID: 33208916
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
3. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
4. Deferred autologous stem cell transplantation in systemic AL amyloidosis.
Manwani R; Hegenbart U; Mahmood S; Sachchithanantham S; Kyriakou C; Yong K; Popat R; Rabin N; Whelan C; Dittrich T; Kimmich C; Hawkins P; Schönland S; Wechalekar A
Blood Cancer J; 2018 Nov; 8(11):101. PubMed ID: 30397193
[TBL] [Abstract][Full Text] [Related]
5. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.
Hwa YL; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Kourelis TV; Gonsalves WI; Rajkumar SV; Go RS; Leung N; Kapoor P; Dingli D; Kyle RA; Russell S; Lust JA; Hayman SR; Lin Y; Zeldenrust S; Dispenzieri A
Am J Hematol; 2016 Oct; 91(10):984-8. PubMed ID: 27341539
[TBL] [Abstract][Full Text] [Related]
6. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
7. Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival.
Tandon N; Muchtar E; Sidana S; Dispenzieri A; Lacy MQ; Dingli D; Buadi FK; Hayman SR; Chakraborty R; Hogan WJ; Gonsalves W; Warsame R; Kourelis TV; Leung N; Kapoor P; Kumar SK; Gertz MA
Bone Marrow Transplant; 2017 Aug; 52(8):1126-1132. PubMed ID: 28394369
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
[TBL] [Abstract][Full Text] [Related]
9. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.
Sidiqi MH; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e108-e111. PubMed ID: 30529461
[TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.
Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250
[TBL] [Abstract][Full Text] [Related]
12. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
13. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis.
Sidana S; Sidiqi MH; Dispenzieri A; Buadi FK; Lacy MQ; Muchtar E; Dingli D; Hayman SR; Gonsalves WI; Kapoor P; Leung N; Warsame R; Kourelis TV; Wolf RC; Hogan WJ; Kumar SK; Gertz MA
Am J Hematol; 2019 Sep; 94(9):1020-1026. PubMed ID: 31254301
[TBL] [Abstract][Full Text] [Related]
14. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.
Muchtar E; Gertz MA; Kumar SK; Lacy MQ; Dingli D; Buadi FK; Grogan M; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Gonsalves W; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Dispenzieri A
Blood; 2017 Apr; 129(15):2111-2119. PubMed ID: 28126928
[TBL] [Abstract][Full Text] [Related]
15. Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis.
Abdallah N; Sidana S; Dispenzieri A; Lacy M; Buadi F; Hayman S; Kapoor P; Leung N; Dingli D; Hwa YL; Lust J; Russell S; Gonsalves W; Go R; Hogan W; Kyle R; Rajkumar SV; Gertz M; Kumar S
Bone Marrow Transplant; 2020 Jul; 55(7):1297-1304. PubMed ID: 32518290
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Fuchida SI; Kawamura K; Sunami K; Tsukada N; Fujii S; Ohkawara H; Usuki K; Wake A; Endo S; Ishiyama K; Ueda Y; Nakamura Y; Miyamoto T; Fukuda T; Ichinohe T; Atsuta Y; Takamatsu H
Transplant Cell Ther; 2022 Feb; 28(2):76-82. PubMed ID: 34774818
[TBL] [Abstract][Full Text] [Related]
17. Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Hassan H; Verma K; Ferri G; Brauneis D; Quillen K; Sloan JM; Sanchorawala V; Edwards CV
Transplant Cell Ther; 2022 Nov; 28(11):761.e1-761.e7. PubMed ID: 35970300
[TBL] [Abstract][Full Text] [Related]
18. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
19. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
20. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation.
Zhang Y; Guo J; Chen W; Zhao L; Huang X
Bone Marrow Transplant; 2024 Mar; 59(3):350-358. PubMed ID: 38148411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]